Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs BSX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BSX Captures Overall Composite Edge (58.8 HOLD vs 31.5 SELL), While EW Leads 4–2 on Growth & Valuation Pillars

BSX Overall Winner 6-Pillar Tally: EW 4 – 2 BSX Matrix Metrics: EW 4 – 6 BSX

As of Nov 16, 2026, Boston Scientific Corp. (BSX) captures the overall head-to-head institutional edge over Edwards Lifesciences Corp (EW) on higher Unified Composite conviction (58.8/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while EW wins 4–2 across the 6-pillar growth and valuation breakdown. EW trades at $106.66 (31.6x Forward P/E, 28.8% operating margin) versus BSX at $43.74 (14.2x Forward P/E, 19.6% operating margin).

  • Growth vs. Quality Trade-Off: BSX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. EW 31.5/100 SELL) and 0.32β · 45% Vol risk profile, whereas EW leads top-line expansion (+10.5% YoY revenue growth, 2.33x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs BSX
EW NYSE
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
BSX NYSE Head-to-Head Winner
Boston Scientific Corp.
Surgical & Medical Instruments & Apparatus
$43.74
-1.35% 1D
Market Cap $64.1B
TTM Revenue $21.1B
Forward P/E 14.2x
Beta / 30D Vol 0.32β · 45% Vol
Unified Composite Score
58.8 / 100 HOLD
Tech 49.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -4.5%) with fading momentum, RSI 49
RSI-14: 49.4 · SMA20: $44.35 · SMA50: $43.94

6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 BSX)

Columns: Metric · EW · BSX
1. Valuation Multiples BSX
Forward P/E 31.6x 14.2x
Trailing P/E 61.5x 18.6x
PEG Ratio 2.33x 0.76x
EV / Revenue 8.8x 3.6x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +1.4%
Earnings Growth (YoY) +6.7% -21.5%
TTM Revenue (USD) $6.67B $21.1B
Market Cap $60.8B $64.1B
3. Profitability & Quality EW
Gross Margin 78.0% 68.0%
Operating Margin 28.8% 19.6%
Net Profit Margin 15.3% 16.6%
Return on Equity (ROE) 9.3% 14.1%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $1.42B $1.46B
Cash Flow Margin 21.3% 6.9%
Net Cash / Leverage $2.41B Net Cash $11.3B Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BSX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 24.6% (34th %ile) 77.2% (53rd %ile)
Put/Call OI Skew N/A 1.01x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 48.4% of Rev ($10.2B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (4) vs BSX (6)
Institutional Metric EW BSX Criterion Row Edge
Market Capitalization
Scale
$60.8B $64.1B Larger Scale BSX
Trailing P/E Ratio
Valuation
61.5x 18.6x Lower Multiple BSX
Forward P/E Ratio
Valuation
31.6x 14.2x Lower Multiple BSX
Revenue Growth (YoY)
Growth
+10.5% +1.4% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 19.6% Higher Margin EW
Net Profit Margin
Profitability
15.3% 16.6% Higher Margin BSX
Return on Equity (ROE)
Capital Efficiency
9.3% 14.1% Higher ROE BSX
52-Week Range Position
Momentum
96% ($75–$108) 6% ($40–$106) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.32β · 45% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 58.8 / 100 (HOLD) Higher Composite BSX
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $21.1B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 68.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev 0.76x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $1.46B ($11.3B Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +24.62 pp
EW: +23.16% · BSX: -1.46%
3M Horizon EW +30.56 pp
EW: +17.23% · BSX: -13.33%
6M Horizon EW +51.23 pp
EW: +29.45% · BSX: -21.78%
1Y Horizon EW +82.19 pp
EW: +23.86% · BSX: -58.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue BSX Revenue EW Op. Margin BSX Op. Margin Margin Leader
FY2018 $3.72B $9.82B 20.1% 15.3% EW
FY2019 $4.35B $10.7B 26.4% 14.1% EW
FY2020 $4.39B $9.91B 20.5% -0.8% EW
FY2021 $5.23B $11.9B 32.3% 10.1% EW
FY2022 $4.46B $12.7B 33.6% 13.0% EW
FY2023 $5.01B $14.2B 26.1% 16.5% EW
FY2024 $5.44B $16.8B 25.3% 15.5% EW
FY2025 $6.07B $20.1B 20.8% 18.0% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BSX CONSOLIDATION
62d in phase · OBV NEUTRAL
Current IV 77.2%
IV Percentile 53rd %ile
Put/Call OI Skew 1.01x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BSX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
BSX Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $64.1B market capitalization and 19.6% operating margin.
OpEx & R&D Reinvestment 48.4% of Rev ($10.2B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs BSX Key Questions & Quantitative Answers

As of Nov 16, 2026, Boston Scientific Corp. (BSX) captures the overall head-to-head institutional edge over Edwards Lifesciences Corp (EW) on higher Unified Composite conviction (58.8/100 HOLD vs. 31.5/100 SELL) after splitting the core matrix 6–4 (led by Valuation Multiples, Options & Positioning), while EW wins 4–2 across the 6-pillar growth and valuation breakdown. EW trades at $106.66 (31.6x Forward P/E, 28.8% operating margin) versus BSX at $43.74 (14.2x Forward P/E, 19.6% operating margin). Growth vs. Quality Trade-Off: BSX earns the overall head-to-head edge with a stronger Unified Composite Score (58.8/100 HOLD vs. EW 31.5/100 SELL) and 0.32β · 45% Vol risk profile, whereas EW leads top-line expansion (+10.5% YoY revenue growth, 2.33x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: EW trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.4); meanwhile BSX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with BSX at +1.4% YoY revenue growth and -21.5% YoY earnings growth on $21.1B TTM revenue (68.0% gross margin, 19.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while BSX shifted +104.4%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 48.4% of Rev ($10.2B) (0 disclosures) for BSX.

BSX screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas BSX trades at 14.2x Forward P/E, 18.6x Trailing P/E, 0.76x PEG, and 3.6x EV/Revenue (6.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus BSX (14.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, BSX carries 77.2% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 1.01x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.